PCRX
$21.94
Pacira BioSciences, Inc.
Recent News
Sector Update: Health Care Stocks Lower Late Afternoon
Health care stocks were slipping late Wednesday afternoon, with the NYSE Health Care Index down 0.5%
Assessing Pacira BioSciences (PCRX) Valuation After Recent Share Price Weakness
Recent share performance and business snapshot Pacira BioSciences (PCRX) has been under pressure recently, with the stock showing a 3% decline over the past day and a 5.6% decline over the past week, while still positive over the past month. At a last close of US$21.91, Pacira carries a value score of 2 and reports annual revenue of US$726.41m and net income of US$7.03m. The company has a specialized focus on non opiod pain management products. See our latest analysis for Pacira...
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down
PCRX misses Q4 earnings and revenue estimates as expenses surge and shares slide, despite Exparel growth and a new 2026 outlook.
Pacira BioSciences, Inc. Q4 2025 Earnings Call Summary
Moby summary of Pacira BioSciences, Inc.'s Q4 2025 earnings call
Pacira BioSciences Q4 Earnings Call Highlights
Pacira BioSciences (NASDAQ:PCRX) executives used the company’s fourth-quarter and full-year 2025 earnings call to highlight what CEO Frank Lee described as a “transformative year,” pointing to renewed EXPAREL volume momentum, strengthened intellectual property protection, expanded reimbursement cove